Back to News
Market Impact: 0.25
Oppenheimer Initiates Coverage of Amneal Pharmaceuticals at Outperform
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Oppenheimer initiated coverage of Amneal Pharmaceuticals (NASDAQ: AMRX) on September 23, 2026, with an Outperform recommendation. The initiation is a positive analyst catalyst for the U.S.-based generic and specialty pharmaceutical company, though the article provides no price target, earnings estimates, or additional investment rationale.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
AMRX0.45
OPY0.10
More News
- AMD shares are primed for a comeback, says Oppenheimer
- Wall Street sets AMD stock price target for next 12 months
- Jim Cramer's top 10 things to watch in the stock market Monday
- RBC Capital initiates Eupraxia Pharmaceuticals stock with outperform rating
- Innoviva stock hits 52-week low at 18.98 USD
- Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval